A durable response to cytarabine in advanced breast cancer.
Cytarabine is a useful agent in the management of acute leukaemias, but is not thought to have activity in solid tumours. We describe the case history of a woman with advanced breast cancer, presenting with superior vena cava obstruction occurring after radiotherapy and chemotherapy, who had a durable remission following inadvertent dosing with cytarabine. A review of the literature reveals that this is the first documented case of a meaningful response to cytarabine in metastatic breast cancer.
Czaykowski
P M
PM
Princess Margaret Hospital, Toronto, Ontario, Canada.
Samuels
T
T
Oza
A
A
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D015412:Mastectomy, Segmental; D008508:Medication Errors; D008875:Middle Aged; D011879:Radiotherapy Dosage; D013479:Superior Vena Cava Syndrome / Q000209:etiology
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine